Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study

Ruiz, Pedro; Martínez-Castrillo, Juan Carlos; Alonso‐Cánovas, Araceli; Bárcenas, A. Herranz; Vela, Lydia; Alonso, Pilar Sánchez; Mata, Marina; Gonzalez, Nuria Olmedilla; Mahíllo‐Fernández, Ignacio

doi:10.1136/jnnp-2013-306787

Cited by 218 publications

(221 citation statements)

References 34 publications

Supporting

Mentioning

191

Contrasting

Unclassified

Order By: Relevance

“…Recent studies suggest ICDs occur in upwards of 40% of PD patients [2], with males more likely to report multiple impulsive behaviours than females [3]. While there are currently no reliable predictive markers for the development of an ICD, patients with higher traits of impulsivity may be more susceptible, although this is yet to be established.…”

Section: Introductionmentioning

confidence: 99%

Sleep Disturbance and Serum Ferritin Levels Associate with High Impulsivity and Impulse Control Disorders in Male Parkinson’s Disease Patients

Anderton¹

2017

AJPN

View full text Add to dashboard Cite

Impulse control disorders (ICDs) occur in a subset of Parkinson's disease (PD) patients on dopaminergic medications however there are currently no reliable markers to identify patients at risk. Sleep disturbances are more common in patients with an ICD. Serum ferritin levels have been associated with PD disease stage and progression, but have not previously been associated with impulsivity levels. The objective of this study was to determine if serum ferritin levels and sleep disturbance are associated with high traits of impulsivity and ICD in a cohort of PD patients attending a movement disorders clinic. This study assessed impulsiveness in 87 PD patients using the Barratt Impulsiveness Scale. Severity of sleep disturbance was determined using the sleep-related items of the MDS-UPDRS. Serum ferritin, iron and transferrin levels were measured in patients, as well as 36 age-matched healthy controls. Serum ferritin levels were significantly elevated in male PD patients in the high impulsivity group compared to patients in the low (p=.022) and normal range groups (p=.024) and showed a linear increase across the three groups. Sleep disturbance also demonstrated a linear trend, which was most severe in the high impulsivity group (p=.030). A subgroup of 11 male PD patients who fulfilled the DSM-5 criteria for an ICD had significantly higher ferritin levels and more severe sleep disturbance when compared with the remaining male PD cohort. Serum ferritin levels and sleep disturbance severity are highlighted as potential markers for abnormal impulsivity and ICD in PD patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Sleep Disturbance and Serum Ferritin Levels Associate with High Impulsivity and Impulse Control Disorders in Male Parkinson’s Disease Patients

Anderton¹

2017

AJPN

View full text Add to dashboard Cite

show abstract

“…Although rotigotine has been reported to confer a lower risk compared with other DAs (Garcia‐Ruiz et al., 2014; Moore, Khalaj, et al., 2014; Rizos et al., 2016), rotigotine has D3 receptor affinity, and furthermore, in a post hoc analysis of six open‐label extension studies, 71 of 786 patients (9%) with rotigotine treatment developed ICB (Antonini et al., 2016). Hence, rotigotine could be a risk factor for the development of ICB.…”

Section: Discussionmentioning

confidence: 99%

The factors associated with impulse control behaviors in Parkinson's disease: A 2‐year longitudinal retrospective cohort study

et al. 2018

View full text Add to dashboard Cite

IntroductionImpulse control behaviors (ICBs) are impulsive–compulsive behaviors often associated with dopamine replacement therapy in Parkinson's disease (PD). Although remission can occur in ICB, only four reports on the ratio of remission and the persistence of ICB have been published, and the associated factors with ICB remission or persistence have been little known. Therefore, we conducted a longitudinal assessment of the remission, persistence, and development of ICB and those associated factors in patients with PD.MethodsWe retrospectively investigated a PD database at Aomori Prefectural Central Hospital, Japan. One hundred and forty‐eight patients with PD who could be followed up for 2 years were enrolled. ICB was assessed using the Questionnaire for Impulsive–Compulsive Disorders in Parkinson's disease. Motor severity (Hoehn and Yahr scale and United Parkinson's Disease Rating Scale), cognitive function (Mini–Mental State Examination), and other clinical variables (sex, age, onset age, disease duration, olfactory dysfunction, and dyskinesia) and medications used to treat PD were assessed. Univariate analyses were performed.ResultsSeven patients were excluded because of the exclusion criteria, and 141 patients were analyzed. Thirty patients (21.3%) had ICB at baseline, and these patients also had significantly higher use of pergolide. The ICB remission rate was 60%, the ICB persistence ratio was 40%, and the ICB development ratio was 12.6% over 2 years. Statistically, younger age and pergolide use were associated with ICB persistence. Being male, having dyskinesia, and rotigotine, entacapone, zonisamide, and istradefylline use were associated with ICB development.ConclusionThis study suggests that younger age and pergolide use may be the new associated factors with ICB persistence and that entacapone, zonisamide, and istradefylline use may be associated with the development of ICB. Drug profiles and medication practices in Japan may explain the association of these factors with ICB.

show abstract

“…Two impulse control disorders were encountered in the current study, as it has been reported previously in small numbers of patients. A recent study was seen that ICD was significantly associated with the use of the nonergolinic oral DA (pramipexole and ropinirole) when compared with transdermal non-ergolinic DA (rotigotine) [4] [14] [18] [19].…”

Section: Discussionmentioning

confidence: 99%

Safety and Tolerability of Transdermal Rotigotine in a Clinical Practice Cohort for 2 Years

Constenla¹,

Pato²,

Hernando³

et al. 2014

WJNS

View full text Add to dashboard Cite

Background: Parkinson's disease (PD) is a progressive neurodegenerative disease that occurs as a result of loss of dopaminergic neurons from the substantia nigra. Rotigotine is a non-ergolinic dopamine agonist available as a silicone-based transdermal patch for the treatment of PD. In the European Union, rotigotine transdermal patch is indicated for use as monotherapy in early idiopathic PD, or in combination with levodopa through the disease course to the late stages where motor complications with levodopa become an issue. Objective: To investigate the safety and tolerability of transdermal rotigotine, in patients with PD being treated during routine clinical practice for 2 years. Results: 114 patients were enrolled, and evaluated for adverse events over a 24-month period. Adverse events occurred in 39 patients (34.21%). 23 patients (20.17%) reported application site reactions (dermatitis, erythema, itching), and 16 (14.03%) had systemic adverse events. Sleep disorders were the most common problem; the others were hallucinations, depression, dizziness, and syncope. No patient experienced dyskinesia. Adverse events necessitated the discontinuation of rotigotine for application site reactions in fourteen patients (12.28%) and 11 patients (9.64%); reasons for discontinuation were systemic adverse events. Conclusion: Rotigotine is safe and well tolerated when used to treat PD in routine clinical practice.

show abstract

Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study

Cited by 218 publications

References 34 publications

Sleep Disturbance and Serum Ferritin Levels Associate with High Impulsivity and Impulse Control Disorders in Male Parkinson’s Disease Patients

Sleep Disturbance and Serum Ferritin Levels Associate with High Impulsivity and Impulse Control Disorders in Male Parkinson’s Disease Patients

The factors associated with impulse control behaviors in Parkinson's disease: A 2‐year longitudinal retrospective cohort study

Safety and Tolerability of Transdermal Rotigotine in a Clinical Practice Cohort for 2 Years

Contact Info

Product

Resources

About